Novo Nordisk enters licence agreement with Australia's G2 Inflammation  

2006.02.10
Denmark's Novo Nordisk has entered a global licence agreement with Australian biotech company G2 Inflammation to collaborate on development and commercialisation of new types of anti-inflammatory therapies based on G2's C5a Receptor antibodies

Danish healthcare company Novo Nordisk has entered a global licence agreement with Australian biotech company G2 Inflammation, a subsidiary of G2 Therapies, to collaborate on development and commercialisation of new types of anti-inflammatory therapies based on G2's C5a Receptor antibodies.

The antibodies licensed under the agreement were first developed by Professor Mackay at the Garvan Institute of Medical research, Sydney. Anti-C5a Receptor therapies have potential application in several important indications including rheumatoid arthritis, writes Novo Nordisk in a press release.

Novo Nordisk regards the agreement with G2 as an important supplement to the company's growing portfolio of biopharmaceutical cancer and inflammation projects. The news was reported by financial daily newspaper Børsen and on the Novo Nordisk website.

Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest product portfolio in the industry, including advanced products in the area of insulin delivery systems. It also has a leading position in areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk is headquartered in Bagsværd, north of Copenhagen, and employs 22,000 people in 79 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London.

Link > Novo Nordisk 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×